3rd Quarter - Report

MERCK & CO, INC. for MERCK & CO INC

Firm
Client
Income
—
Expenses
$890,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Agriculture AGR

Funding levels for the Center for Veterinary Biologics in the Animal and Plant Health Inspection Service at the United State Department of Agriculture.

LobbyistCovered position, as disclosed
BRADLEY ALLEN ROSSIN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Taxation/Internal Revenue Code TAX

Tax Reform, Generally

LobbyistCovered position, as disclosed
BRADLEY ALLEN ROSSIN —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

Intellectual Property, US-Mexico-Canada Agreement and US-China trade

LobbyistCovered position, as disclosed
ROBERT FILIPPONE —
COURTNEY LEE-ASHLEY —
COREY MALMGREN —
BRADLEY ALLEN ROSSIN —
ELIZABETH SCHWARTZ —

Contacted: Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 340B Reforms, Drug pricing, Anti-microbial Resistance, General Pharmaceutical issues transparency, formulary design, prescription drug coverage, Biosimiliars, Cost and value of medicines, Maternal Health, Affordable Care Act, Importation, Vaccines.

LobbyistCovered position, as disclosed
ERIN DARLING —
ROBERT FILIPPONE —
COURTNEY LEE-ASHLEY —
COREY MALMGREN —
BRADLEY ALLEN ROSSIN —
ELIZABETH SCHWARTZ —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS)

Bills named: H.R. 4597 (116th), S. 1712 (116th), S. 2543 (116th), H.R. 4455 (116th), H.R. 3 (116th), H.R. 4100 (116th), H.R. 4629 (116th), H.R. 2296 (116th)

Medicare/Medicaid MMM

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019 S. 1437, Drug-price Transparency in Communications (DTC) Act Medicaid, Medicare, Medicare Part B, Medicaid Rebate Cap, 340B reforms Medicare Part D, Part D inflationary rebate, International pricing index, Drug Pricing and Center for Medicare & Medicaid Demonstrations.

LobbyistCovered position, as disclosed
ERIN DARLING —
ROBERT FILIPPONE —
COURTNEY LEE-ASHLEY —
COREY MALMGREN New —
BRADLEY ALLEN ROSSIN —
ELIZABETH SCHWARTZ —

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 62 (116th), H.R. 107 (116th), S. 1437 (116th), S. 475 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.